PT - JOURNAL ARTICLE AU - Xianding Deng AU - Miguel A Garcia-Knight AU - Mir M. Khalid AU - Venice Servellita AU - Candace Wang AU - Mary Kate Morris AU - Alicia Sotomayor-González AU - Dustin R Glasner AU - Kevin R Reyes AU - Amelia S. Gliwa AU - Nikitha P. Reddy AU - Claudia Sanchez San Martin AU - Scot Federman AU - Jing Cheng AU - Joanna Balcerek AU - Jordan Taylor AU - Jessica A Streithorst AU - Steve Miller AU - G. Renuka Kumar AU - Bharath Sreekumar AU - Pei-Yi Chen AU - Ursula Schulze-Gahmen AU - Taha Y. Taha AU - Jennifer Hayashi AU - Camille R. Simoneau AU - Sarah McMahon AU - Peter V. Lidsky AU - Yinghong Xiao AU - Peera Hemarajata AU - Nicole M. Green AU - Alex Espinosa AU - Chantha Kath AU - Monica Haw AU - John Bell AU - Jill K. Hacker AU - Carl Hanson AU - Debra A. Wadford AU - Carlos Anaya AU - Donna Ferguson AU - Liana F. Lareau AU - Phillip A. Frankino AU - Haridha Shivram AU - Stacia K. Wyman AU - Melanie Ott AU - Raul Andino AU - Charles Y. Chiu TI - Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation AID - 10.1101/2021.03.07.21252647 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.07.21252647 4099 - http://medrxiv.org/content/early/2021/03/09/2021.03.07.21252647.short 4100 - http://medrxiv.org/content/early/2021/03/09/2021.03.07.21252647.full AB - We identified a novel SARS-CoV-2 variant by viral whole-genome sequencing of 2,172 nasal/nasopharyngeal swab samples from 44 counties in California. Named B.1.427/B.1.429 to denote its 2 lineages, the variant emerged around May 2020 and increased from 0% to >50% of sequenced cases from September 1, 2020 to January 29, 2021, exhibiting an 18.6-24% increase in transmissibility relative to wild-type circulating strains. The variant carries 3 mutations in the spike protein, including an L452R substitution. Our analyses revealed 2-fold increased B.1.427/B.1.429 viral shedding in vivo and increased L452R pseudovirus infection of cell cultures and lung organoids, albeit decreased relative to pseudoviruses carrying the N501Y mutation found in the B.1.1.7, B.1.351, and P.1 variants. Antibody neutralization assays showed 4.0 to 6.7-fold and 2.0-fold decreases in neutralizing titers from convalescent patients and vaccine recipients, respectively. The increased prevalence of a more transmissible variant in California associated with decreased antibody neutralization warrants further investigation.Competing Interest StatementDr. Charles Chiu receives support for SARS-CoV-2 research unrelated to this study from Abbott Laboratories and Mammoth Biosciences. The other authors declare no competing interests.Funding StatementThis work has been funded by a Laboratory for Genomics Research (LGR) Excellence in Research Award (LFL), a Fast Grant from Emergent Ventures (SKW), the Innovative Genomics Institute (CYC, MO, LFL, SW, PF, HS), the New Frontiers in Research Fund provided by the Canadian Institutes of Health Research (CYC), the Roddenberry Foundation (MO), and NIH grants R33-AI129455 (CYC) and 5DP1DA038043 (MO).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:nical samples from state and county public health laboratories were collected and sequenced as part of routine public health surveillance activities. Clinical samples from the IGI were sequenced under a waiver from the UC Berkeley Office for the Protection of Human Subjects. Clinical samples from UCSF were collected for a biorepository and sequenced according to protocols approved by the UCSF Institutional Review Board (protocol number 10-01116, 11-05519).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAssembled SARS-CoV-2 genomes in this study were uploaded to GISAID (Elbe and Buckland-Merrett, 2017; Shu and McCauley, 2017) (accession numbers in Supplementary Table 1) and can be visualized in NextStrain. Viral genomes were also submitted to the National Center for Biotechnology Information (NCBI) GenBank database (accession numbers pending). Raw sequence data were submitted to the Sequence Read Archive (SRA) database (BioProject accession number PRJNA171119, Chiu laboratory at UCSF; BioProject accession number PRJNA639591, Wyman laboratory at UC Berkeley).